Valencia company tracks cholesterol

first_imgMolecular Profiling is incorporating genetic discoveries from the Human Genome Project. (661) 257-5253 160Want local news?Sign up for the Localist and stay informed Something went wrong. Please try again.subscribeCongratulations! You’re all set! VALENCIA – In the balance between good and bad cholesterol, a panel of tests could help doctors pinpoint potential problems for heart patients. Valencia-based Specialty Laboratories collaborated with a Phoenix company and a handful of doctors to create the CardioEvaluatR testing program. The program provides results quicker than others, said Ron Blum, vice president of marketing for Specialty Laboratories. Doctors describe high-density lipoprotein, or HDL, as good cholesterol, and low-density lipoprotein, or LDL, as bad cholesterol. They say it’s important to get more detailed information on both in a patient’s body. “The total cholesterol really doesn’t give us much information about an individual at all, as far as what his risks are,” said Dr. Arthur Agatston, a cardiologist and the creator of the South Beach Diet. Agatston worked on CardioEvaluatR as a consultant for Molecular Profiling Institute Inc., the company that collaborated with Specialty. The CardioEvaluatR is a panel of tests that gives quick results breaking down different types of HDL and LDL, triglycerides, insulin levels and more. While the results of some testing programs are not available for several weeks, CardioEvaluatR results are available within five days, Blum said. “It’s faster, very accurate and has a whole group of experts that are really backing the panel,” Blum said. Those include Dr. P.K. Shah, director of the cardiology division at Cedars-Sinai Medical Center. Specialty Laboratories, which has 700 employees, will receive blood samples from patients and conduct all the testing at its Valencia facility. In the future, other labs could use the testing program, Blum said. Agatston is excited about the prospect of more genetic evaluations being included in the program. “I suspect in the fairly near future, … it’s going to add a completely new dimension to how we treat heart disease.” last_img read more